Arena Pharma (ARNA) Receives Day 180 from CHMP for Belviq
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Obesity Pill Makers in Focus as EMA CHMP Denies Belviq MAA (ARNA) (VVUS) (OREX)
January 22, 2013 1:48 PM ESTVIVUS, Inc. (Nasdaq: VVUS) and Orexigen (Nasdaq: OREX) are seeing some notable pressure following disclosure by Arena Pharmaceuticals (Nasdaq: ARNA) that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use... More
